GET DAILY SIGNALSWhy Is Natera (NTRA) Stock Down -14.11% Today?
Key Takeaways
- Shares of Natera fell about 14.11% on Friday, dropping from a prior close of $363.76 to roughly $312.42 in intraday trading.
- The primary catalyst was a steeper-than-expected third-quarter loss despite a strong revenue beat, as elevated spending outpaced analyst earnings forecasts.
- A simultaneous CEO transition—with Steve Chapman stepping down and Solomon Moshkevich taking over immediately—added uncertainty to the reaction.
- Weakness across blood-testing peers, including Grail and Guardant Health, compounded the sector-wide selling pressure.
- Investors are now watching how the new leadership executes on the company's raised full-year revenue guidance and its $6 billion 2029 target.
- For deeper data on this ticker, explore the Price Targets, Earnings, and Forecast pages for NTRA.
- To see which automated strategies are performing best in the current market, visit Trending AI Robots.
Opening Summary
Natera, Inc. (NTRA), an Austin, Texas-based leader in cell-free DNA testing and precision medicine, saw its shares plunge on Friday. The stock traded around $312.42, down roughly 14.11% from Thursday's closing price of $363.76. The selloff was driven almost entirely by company-specific developments rather than broader market conditions, as investors digested a mixed third-quarter earnings report alongside an abrupt leadership change announced after the market closed on Thursday.
Earnings Results: A Profitability Miss
The sharp market reaction stemmed from Natera's third-quarter 2026 financial results. The company generated revenue of roughly $794 million, up about 34% year over year and well ahead of Wall Street's consensus near $708 million. However, the bottom line disappointed. Natera reported a GAAP loss of $0.42 per share, significantly wider than the approximately $0.27–$0.29 loss analysts had projected—a miss of about $0.15 per share.
The wider loss reflected continued heavy investment. Operating expenses rose sharply, with research and development spending climbing about 40% year over year, alongside higher commercial and biopharma-related costs. While revenue growth remained robust and the net loss narrowed versus the prior-year period, the market focused on the fact that profitability remains elusive even as the top line keeps beating expectations.
CEO Transition Adds Uncertainty
Compounding the earnings-driven move, Natera simultaneously announced a leadership change. Longtime CEO Steve Chapman stepped down and was replaced effective immediately by Solomon Moshkevich, previously president of the company's Clinical Diagnostics business. Moshkevich, a 15-year Natera veteran who spearheaded the company's expansion into oncology, takes the helm during a delicate phase of heavy spending and competitive pressure. Chapman will remain as a consultant and board advisor, but the abrupt timing of the transition—coupled with the earnings miss—introduced an element of uncertainty that amplified the selloff.
Sector Pressure From Blood-Testing Peers
The decline also reflected broader weakness across the genetic and blood-testing sector. Rival Grail reported disappointing sales of its cancer-detection test Galleri earlier in the week, which pressured sentiment across the liquid biopsy space. Guardant Health, another close competitor in cancer-focused blood testing, also fell after its own quarterly results. This sector-wide selling reinforced Natera's move, as investors broadly de-risked their exposure to high-multiple diagnostics names that are still spending aggressively to build out their franchises.
Market Context and Trading Activity
The stock's slide stood out against a generally resilient market backdrop. While major indices were mixed to modestly higher on the day, Natera moved sharply lower, underscoring that the move was driven by company-specific news rather than macroeconomic headwinds. Trading volume was elevated as investors repositioned following the earnings release and leadership announcement. From a technical perspective, shares undercut key support levels and their 50-day moving average, sending the stock toward multi-week lows and well below its 52-week high of $437.41.
What Comes Next for NTRA
Looking ahead, investors will focus on execution under new leadership. Despite the earnings miss, management raised full-year 2026 revenue guidance to a range of $3.005 billion to $3.035 billion—a roughly $140 million increase at the midpoint—and introduced a target of $6 billion in revenue by 2029. Near-term catalysts include potential reimbursement decisions for the Signatera molecular residual disease test, pending regulatory submissions, and a colorectal cancer screening readout expected in 2027. Key risks include continued operating-expense growth, competitive pressure in liquid biopsy, and the execution risk inherent in a leadership transition. Some analysts have reiterated bullish ratings, but the market's immediate focus remains on whether the company can translate its revenue growth into sustained profitability.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, each with distinct strategies, timeframes, performance metrics, and traded symbols. Rather than surfacing every bot, the curated Trending AI Robots section highlights only the strongest performers under current market conditions. Exploring this page can help you identify automated strategies that are currently outperforming and evaluate whether they align with your own approach.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
NTRA in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 05, 2026
NTRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 34 cases where NTRA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for NTRA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where NTRA advanced for three days, in 246 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NTRA as a result. In 80 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for NTRA turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 38 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.
NTRA moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NTRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
The Aroon Indicator for NTRA entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.585) is normal, around the industry mean (67.298). NTRA's P/E Ratio (-230.126) is considerably lower than the industry average of (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (17.857) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 25 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. NTRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 71 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a genetic testing company which develops proprietary bioinformatics-based technology
Industry MedicalSpecialties
Advertisement